The study, led by Dr. Gilberto Lopes, chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, compared zipalertinib plus platinum‑based chemotherapy against chemotherapy alone in the first‑line setting for EGFR exon 20 insertion NSCLC. Median progression‑free survival (PFS) was 14.5 months with the combination versus 8.5 months with chemotherapy alone, yielding a hazard ratio (HR) of 0.50 (95 % CI 0.34–0.73; p = 0.00015).
Objective response rates (ORR) also favored the experimental arm, with 65.0 % of patients achieving a tumor response compared with 40.3 % in the control group. The median duration of response (DoR) was extended to 14.2 months versus 9.9 months, respectively.
In a prespecified subgroup of patients with baseline brain metastases, the combination therapy showed an even larger PFS benefit, with an HR of 0.38, suggesting activity against intracranial disease.
Overall survival (OS) data remain immature; the hazard ratio was 0.72 (95 % CI 0.42–1.23) and median OS had not been reached at a median follow‑up of 10.9 months. Approximately 64.2 % of patients in the chemotherapy arm crossed over to receive zipalertinib after progression.
The efficacy gains came with a substantial increase in grade 3 or higher treatment‑related adverse events (TRAEs): 80.7 % of patients receiving zipalertinib plus chemotherapy experienced severe toxicities versus 40.4 % in the chemotherapy‑only arm, the majority being cytopenias associated with platinum agents.
Dr. Lopes concluded that zipalertinib combined with chemotherapy represents a highly active first‑line option for this molecularly defined NSCLC population, but emphasized the need to balance the pronounced hematologic toxicity against the clinical benefit.
If confirmed in longer follow‑up and broader patient cohorts, the regimen could reshape treatment algorithms for EGFR exon 20 insertion NSCLC, a subgroup historically lacking effective targeted therapies.